Merit Medical Launches Expanded Maestro® Microcatheter Line
New multipurpose microcatheter length complements Merit’s radial-first legacy […]
New multipurpose microcatheter length complements Merit’s radial-first legacy […]
GE and Mayo Clinic plan to collaborate on imaging, artificial intelligence and cancer treatment. […]
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix […]
Funding to Support Research and Expanded Access of Investigational Drug in ALS SALT LAKE CITY, Oct. 05, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological […]
LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), a pioneer of smart baby monitoring, is on a mission to raise critical funds for research that could bring an end to sudden infant death syndrome (SIDS). Owlet is partnering in this effort with Dr. Carmel Harrington, Honorary Research Fellow at Sydney Children’s Hospital […]
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood […]
Medical Technology Company Focused on Vessel Preparation, Dilation, And Treatment Delivery Secures Series B Funding […]
Biomerics Announces Completion of 100,000 sq. ft. Expansion of Brooklyn Park, MN, Facility […]
Audio-based Detection of Anxiety and Depression via Vocal Biomarkers […]
Marcy-l’Étoile (France), September 22nd, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, has submitted the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel to U.S. Food and Drug Administration (FDA) for a dual 510(k) clearance and CLIA1-waiver. This panel is already CE-marked (IVDD2). […]
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in […]
SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social and Governance report, highlighting key efforts that reflect its commitment to conduct operations as a responsible, equitable and sustainable partner in the healthcare industry. “At Myriad, […]